Santhera Pharmaceuticals is hoping this week to provide EU regulators with the information they need to recommend that the company’s drug, Raxone (idebenone), be approved in the EU for the additional indication of Duchenne muscular dystrophy (DMD).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?